Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
- Development stage
- Approved
- Lead developer
- John Robbins
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is a vaccine designed to prevent invasive infections caused by *Haemophilus influenzae* type b (Hib) bacteria. It is a conjugate vaccine, meaning it consists of the capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP) from *H. influenzae* type b strain 1482, which is covalently bound to tetanus toxoid. The tetanus toxoid acts as a carrier protein, enhancing the immune response by recruiting T-cell help, particularly in young children. This mechanism leads to the production of protective anti-PRP antibodies and immunological memory, thereby preventing severe Hib-related diseases such as meningitis, epiglottitis, pneumonia, pericarditis, and septic arthritis. The vaccine is administered intramuscularly and is widely recommended for routine immunization in infants and children.
- Brand names
- ActHIB
- Other names
- Hib vaccineHaemophilus b conjugate vaccinePRP-T
Beyond the preview
Go deeper on Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen.